NovAccess Global Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dwain K. Morris-Irvin
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8834 Mayfield Road New York NY United States of America 44026
- IPO Date
- Sep 21, 1998
- CIK
- 0001039466
- Website
- novaccessglobal.com
- Similar Companies
- Business
- NovAccess Global Inc. (XSNX) is a US-based biopharmaceutical company that develops novel immunotherapies for brain tumor patients, particularly glioblastoma multiforme; its core product is the patented TLR-AD1 platform, a dendritic cell-based immunotherapy that trains immune cells using toll-like receptor agonists and tumor-specific antigens to enhance the body's defense against cancer; the company also advances precision medicine initiatives incorporating AI, big data, and predictive analytics for personalized cancer treatment protocols and physician reports. Founded in 1997 and headquartered at 8584 Washington Street, Suite 127, Chagrin Falls, Ohio, NovAccess Global operates primarily in the United States with emerging collaborations extending data access to Southeast Asia and focuses on the biotechnology segment of healthcare, targeting oncology patients through clinical-stage research and development. Recent developments include a $10.7 million financing agreement in January 2024 with an affiliate of Sumner Global LLC, comprising $3.63 million in common stock and $7.05 million in convertible notes; a partnership announced in 2023 with CKN Ventures Limited to expand clinical datasets for its new AI-driven Precision Medicine Division; another 2023 alliance with BCN Biosciences for oncology drug development; and a May 2024 patent filing with Cedars-Sinai Medical Center to advance its brain cancer vaccine platform.
Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)
NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review
NovAccess Global Advisory on Annual Meeting of Shareholders
NovAccess Global Announces New License to Advance its Immunotherapy Platform
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
NovAccess Global Announces $10.7 Million Financing
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
NovAccess Global to Present at World Orphan Drug Congress
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress